MicroRNAs in papillary thyroid cancer: what is new in diagnosis and treatment
Introduction Papillary thyroid cancer (PTC) accounts for up to 80% of thyroid malignancies.
New diagnostic and therapeutic options are suggested including innovative molecular …
New diagnostic and therapeutic options are suggested including innovative molecular …
Ubiquitin-modifying enzymes in thyroid cancer: Mechanisms and functions
X Xiong, BB Huang, Z Gan, W Liu, Y Xie, J Zhong… - Heliyon, 2024 - cell.com
Thyroid cancer is the most common malignant tumor of the endocrine system, and evidence
suggests that post-translational modifications (PTMs) and epigenetic alterations play an …
suggests that post-translational modifications (PTMs) and epigenetic alterations play an …
Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway
Aberrant expressions of apoptotic genes have been associated with papillary thyroid
carcinoma (PTC) in the past, however, their prognostic role and utility as biomarkers remains …
carcinoma (PTC) in the past, however, their prognostic role and utility as biomarkers remains …
[HTML][HTML] Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation
S Liu, F Xie, L Gan, T Peng, X Xu, S Guo, W Fu… - Genomics, 2020 - Elsevier
The extremely high proliferation rate of tumor cells contributes to pancreatic cancer (PC)
progression. Runt-related transcription factor 1 (RUNX1), a key factor in hematopoiesis that …
progression. Runt-related transcription factor 1 (RUNX1), a key factor in hematopoiesis that …
A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis
X Zou, F Gao, ZY Wang, H Zhang, QX Liu… - Chinese Medical …, 2020 - mednexus.org
Background: Accumulating evidence has revealed that circulating microRNAs (miRNAs) can
serve as non-invasive biomarkers for cancer diagnosis. This study aimed to identify …
serve as non-invasive biomarkers for cancer diagnosis. This study aimed to identify …
MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer
S Xiao, M Zhang, C Liu, D Wang - Molecular Genetics and Genomics, 2018 - Springer
Cisplatin is one of the most popular chemotherapeutic drugs in treating ovarian cancer.
Resistance to cisplatin is a common clinical challenge that needs to be solved to increase its …
Resistance to cisplatin is a common clinical challenge that needs to be solved to increase its …
Functional loss of tumor suppressor genes detected by loss of heterozygosity, but not driver mutations, predicts aggressive lymph node status in papillary thyroid …
S Finkelstein, VA Timmaraju, S Samankan… - … -Research and Practice, 2023 - Elsevier
Background Recognizing aggressive tumor biology is essential to optimizing patient
management for papillary thyroid carcinomas (PTC). Aggressive lymph node (ALN) status is …
management for papillary thyroid carcinomas (PTC). Aggressive lymph node (ALN) status is …
[HTML][HTML] The association of the BRAF-V600E mutation with the expression of the molecular markers in the primary tumor and metastatic tissue in papillary thyroid …
LV Spirina, SY Chizhevskaya, IV Kovaleva… - Asian Pacific Journal …, 2021 - ncbi.nlm.nih.gov
Objective: The aim of this study was investigation the AKT/mTOR signaling pathway
components, transcriptional and growth factors, as well as steroid hormone receptors and …
components, transcriptional and growth factors, as well as steroid hormone receptors and …
Dysregulation of microRNAs as the risk factor of lymph node metastasis in papillary thyroid carcinoma: Systematic review
R Laukiene, V Jakubkevicius… - Endokrynologia …, 2021 - journals.viamedica.pl
Papillary thyroid carcinoma (PTC) has an excellent prognosis with a relatively low mortality
rate, but a small portion of PTC patients suffer from an aggressive form of the disease. In …
rate, but a small portion of PTC patients suffer from an aggressive form of the disease. In …
甲状腺癌RNA 分子研究进展
林琳， 刘建华， 吴丽娜 - 肿瘤防治研究, 2019 - zlfzyj.com
甲状腺癌是内分泌系统中最常见的恶性肿瘤, 约占全身恶性肿瘤的1%. 目前在DNA
水平研究甲状腺癌的发病机制已经相对成熟, 但mRNA, miRNA, lncRNA, circRNA 等不同RNA …
水平研究甲状腺癌的发病机制已经相对成熟, 但mRNA, miRNA, lncRNA, circRNA 等不同RNA …